Compare Merck & Co., Inc. (MRK) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs D Wave Quantum Inc — how do they compare? Merck & Co., Inc. trades at $145.83 (market cap $351.28B), while D Wave Quantum Inc trades at $14.58 (market cap $5.54B). The key difference: Merck & Co., Inc. is far larger — about 63.4× D Wave Quantum Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and D Wave Quantum Inc for 32 Days on average.
| MRK | QBTS | |
|---|---|---|
Market Cap | $351.28B | $5.54B |
Volume | 7,969,665 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $156.43 | $44.78 |
52-Week Low | $82.49 | $12.98 |
Typical Hold Time | 98 Days | 32 Days |
Enterprise Value | $398.04B | $5.04B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
D-Wave Quantum (QBTS) trades at $14.52, down 4.6% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $355 million in 2025 on $25 million in revenue, with a deeply negative net income margin. However, all 13 analysts covering the stock maintain a Buy rating with a consensus price target of $34.38, suggesting significant upside potential from current levels.
The outlook is highly speculative, balancing substantial analyst optimism against severe financial losses and ongoing securities investigations. Investment opportunity hinges on the company's ability to commercialize quantum technology, but risks include cash burn, competitive pressures, and legal uncertainties that could impede shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
